AMRI closes Bothell site, integrates in vitro services with drug discovery

Monday, December 3, 2012 09:58 AM

As the next step in its Smartsourcing strategy, AMRI, a global contract research and manufacturing organization, has taken further actions to expand and better integrate its in vitro biology services with its total drug discovery service platform.

As a result of shifting market preferences related to integrated drug discovery activities, AMRI will further optimize its location footprint by closing its site in Bothell, Wash. The site’s biology capabilities will transition to AMRI’s fully integrated discovery location in Singapore and certain analytical capabilities will consolidate into AMRI’s analytical quality group in Albany, N.Y. The Bothell location employs 24 people.

AMRI estimates that it will incur certain one-time cash and non-cash charges related to the reduction in force and other transition activities of approximately $11 million, of which approximately $5 million in non-cash charges will be incurred in the fourth quarter. AMRI expects the actions will generate annual savings of approximately $2 million. Further details will be available in a Form 8-K filing.

“By further aligning and integrating our global biology services, AMRI continues to address and anticipate changes in the marketplace, strengthening our position as a premier provider of integrated drug discovery services,” said Thomas E. D’Ambra, Ph.D., chairman, president and CEO of AMRI. “Already our Smartsourcing initiatives are proving effective as evidenced by expanded contract services opportunities; this next move provides us the potential to better pursue these opportunities as we enter 2013. We will continue to focus on improving our cost structure and capabilities in order to build stronger and long-term relationships with existing and new customers. AMRI has been known as a top chemistry service company for many years, and this will help the marketplace to also integrate our top-level biology offerings.”

The realignment will be phased in over several months, with the cessation of the Bothell operation expected by the end of the first quarter of 2013.

Share:          
CLINICAL TRIAL RESOURCES

Search:

NEWS ONLINE ARCHIVE

Browse by:

CWWeekly

February 25

Analysts: With market anticipation of Quintiles IPO, other CROs could soon file to go public

National Clinical Trial Network aims to link sponsors, minority patients for trials and access to new therapies

Already a subscriber?
Log in to your digital subscription.

Subscribe to CWWeekly.

The CenterWatch Monthly

March

Sites rate the best
sponsors of 2013

Largest survey response ever puts Biogen Idec, Forest Labs, Bayer at top

As CRO industry
turns 30, a look back
at modest beginnings

Phenomenal growth, strategic partnering highlight evolution
of CROs

Already a subscriber?
Log in to your digital subscription.

Purchase the March issue.

Subscribe to
The CenterWatch Monthly.

The CenterWatch Monthly

February

Sized out of big deals,
mid-tier CROs still thriving

Finding market niches, strategies to stay vital in changing research enterprise

Industry leaders embrace disruptive innovations
Despite resistance to change, many exploring data sharing, open-source collaboration

Already a subscriber?
Log in to your digital subscription.

Purchase the February issue.

Subscribe to
The CenterWatch Monthly.

JobWatch centerwatch.com/jobwatch

Featured Jobs